In conclusion, concurrent expression of NAP in VV promotes humoral immunity against the co-expressed immunogen, which contributed to the therapeutic outcome, whereas similar construction in SFV-based OV generates a higher anti-viral response, without any additional anti-tumor response. Here, CTNNBL1 is linked to neoplasm.